Key result
Tandem high-dose chemotherapy and autologous stem cell transplantation in pediatric patients with solid tumors did not significantly impair cardiac function at 1 year (mean LVEF 65.7%).
Why the study?
Does tandem high-dose chemotherapy and autologous stem cell transplantation impair cardiac function in pediatric patients with solid tumors?
Cohort (n=56)
No
Does tandem high-dose chemotherapy and autologous stem cell transplantation impair cardiac function in pediatric patients with solid tumors?
Tandem high-dose chemotherapy and autologous stem cell transplantation does not appear to significantly impair echocardiographic cardiac function at one year in pediatric patients with solid tumors.
May support short-term cardiac safety of tandem HDCT/auto-SCT in pediatric solid tumors; leaves open longer-term effects and need for prospective validation.
Background: Even though the five year survival rate and prognosis of childhood solid tumors have been improved through the introduction of dose-escalation using tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT), changes in cardiac function have not yet been studied. We therefore evaluated cardiac function after tandem HDCT/auto-SCT. Methods: This study retrospectively analyzed 56 pediatric patients who were diagnosed with solid tumors and who underwent tandem HDCT/auto-SCT at Samsung Medical Center. We investigated the cardiac function of these patients using echocardiography to evaluate the parameters of the left ventricular ejection fraction, e/e ’, and left ventricular Tei index. Results: The mean left ventricular ejection fraction, e/e’, and left ventricular Tei index at one year after the second HDCT/auto-SCT were 65.7%, 0.32, and 8.6, respectively. When compared those with before the first tandem HDCT/auto-SCT, there were no significant negative changes. We evaluated the changes in cardiac function in different subgroups, based on doxorubicin, radiotherapy involving heart, and the age of the patient at diagnosis. There were no significant changes of cardiac function after the treatment in any of the subgroups. Clinical heart failure did not develop in any of the patients.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2014) conducted a cohort in Solid tumors (n=56). Tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) vs. Baseline (before the first tandem HDCT/auto-SCT) was evaluated on Left ventricular ejection fraction. Tandem high-dose chemotherapy and autologous stem cell transplantation in pediatric patients with solid tumors did not significantly impair cardiac function at 1 year (mean LVEF 65.7%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: